Building A Better Patient Registry: Keep It Simple, But Let It Be Big
This article was originally published in The Pink Sheet Daily
Executive Summary
As outcomes research, comparative effectiveness and drug safety worries increasing drive the need for post-market data, sponsors are turning to patient registries for a low-cost way to generate valuable clinical information.
You may also be interested in...
Registries Rising: FDA Looking At TNF Inhibitors; AHRQ Updates Standards
The FDA Amendments Act of 2007 gave the agency many new safety powers and the potential for promotional restrictions and post-marketing fines have understandably received much industry attention. But FDA also appears to be drawing upon its beefed-up authority to increase use of a much older, low-tech safety effort: the patient registry
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.